NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UnitedHealth Group Incorporated (“UnitedHealth” or the “Company”) (NYSE: UNH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980

The investigation concerns whether UnitedHealth and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On February 27, 2024, The Wall Street Journal (“WSJ”) reported that the U.S. Department of Justice (“DOJ”) has launched an antitrust investigation into UnitedHealth. Specifically, the WSJ reported that DOJ investigators have been interviewing healthcare industry representatives in sectors where UnitedHealth competes to determine the possible impacts of acquisitions made through its health services arm, Optum.

On this news, UnitedHealth’s stock price fell $27.04 per share, or 5.15%, over the following two trading sessions, to close at $498.28 per share on February 28, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.